- Home
- CLLS vs XFOR Comparison
CLLS vs XFOR Comparison
Compare CLLS & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | XFOR |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | France | United States |
| Employees | N/A | 143 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 407.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CLLS | XFOR |
|---|---|---|
| Price | $3.72 | $4.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $8.50 | ★ $9.00 |
| AVG Volume (30 Days) | 36.5K | ★ 420.4K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $0.17 |
| 52 Week High | $5.48 | $6.63 |
Technical Indicators
Market Signals| Indicator | CLLS | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.38 | 52.48 |
| Support Level | $3.39 | $3.41 |
| Resistance Level | $3.83 | $4.16 |
| Average True Range (ATR) | 0.17 | 0.31 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 80.92 | 49.38 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.